Donald Husereau
Donald Husereau
Adjunct Professor

BSc, Pharm, MSc

DON HUSEREAU works with private and public sector life sciences organizations to help them understand the value of health technology and its implications for health and innovation policy. He has authored extensive work on the role and value of innovation, including commissioned reports for the Health Canada’s Federal Commission on Innovation (the Naylor Commission), the Canadian Institute of Health Information, Health Canada, the CD Howe Institute, and the Canadian Agency for Drugs and Technologies in Health. He is currently Chair of an International Task Force that has developed consolidated health economic evaluation reporting standards (CHEERS) that is now endorsed by leading biomedical and health policy journals. As an expert in health economics and health technology assessment, Don is currently an Editorial Advisor for the biomedical journals, Pharmacoeconomics and BMC Medicine. He is also currently a Senior Associate of Alberta's Institute of Health Economics.

Selected Publications (past 5 years)

Staniszewska S, Jakab I, Low E, Mossman J, Posner P, Husereau D, et al. Commentary: Advocating for patient and public involvement and engagement in health economic evaluation. Res Involv Engagem. 2023;9:45.

Parmar A, Dai WF, Dionne F, Geirnaert M, Denburg A, Ahuja T, et al. Development of a Multi-Criteria Decision Analysis Rating Tool to Prioritize Real-World Evidence Questions for the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration. Curr Oncol. 2023;30:3776–86.

Palmer S, Borget I, Friede T, Husereau D, Karnon J, Kearns B, et al. A Guide to Selecting Flexible Survival Models to Inform Economic Evaluations of Cancer Immunotherapies. Value Health. 2023;26:185–92.

Oortwijn W, Husereau D, Abelson J, Barasa E, Bayani DD, Canuto Santos V, et al. Designing and Implementing Deliberative Processes for Health Technology Assessment: A Good Practices Report of a Joint HTAi/ISPOR Task Force. Value Health. 2022;25:869–86.

Kunst N, Siu A, Drummond M, Grimm SE, Grutters J, Husereau D, et al. Consolidated Health Economic Evaluation Reporting Standards - Value of Information (CHEERS-VOI): Explanation and Elaboration. Value Health. 2023;26:1461–73.

Husereau D, Villalba E, Muthu V, Mengel M, Ivany C, Steuten L, et al. Progress toward Health System Readiness for Genome-Based Testing in Canada. Curr Oncol. 2023;30:5379–94.

Husereau D, Sullivan T, Feilotter HE, Gomes MM, Juergens R, Sheffield BS, et al. Optimizing the delivery of genetic and advanced diagnostic testing in the province of Ontario: challenges and implications for laboratory technology assessment and management in decentralized healthcare systems. J Med Econ. 2022;25:993–1004.

Husereau D, Steuten L, Muthu V, Thomas DM, Spinner DS, Ivany C, et al. Effective and Efficient Delivery of Genome-Based Testing-What Conditions Are Necessary for Health System Readiness? Healthcare (Basel). 2022;10:2086.

Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, et al. Correction to: Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations. Appl Health Econ Health Policy. 2022;20:781–2.

Culyer A, Husereau D. Redefining Health Technology Assessment: A Comment on “The New Definition of Health Technology Assessment: A Milestone in International Collaboration.” Int J Technol Assess Health Care. 2022;38:e54.

Mateo J, Steuten L, Aftimos P, et al. Delivering precision oncology to patients with cancer. Nat Med. 2022;28(4):658-665. doi:10.1038/s41591-022-01717-2

Husereau D, Drummond M, Augustovski F, et al. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations. Pharmacoeconomics. 2022;40(6):601-609. doi:10.1007/s40273-021-01112-8

Husereau D, Drummond M, Augustovski F, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022 Explanation and Elaboration: A Report of the ISPOR CHEERS II Good Practices Task Force. Value Health. 2022;25(1):10-31. doi:10.1016/j.jval.2021.10.008

Augustovski F, García Martí S, Espinoza MA, Palacios A, Husereau D, Pichon-Riviere A. Estándares Consolidados de Reporte de Evaluaciones Económicas Sanitarias: adaptación al español de la lista de comprobación CHEERS 2022. Value Health Reg Issues. 2022;27:110-114. doi:10.1016/j.vhri.2021.11.001

Zoratti MJ, Pickard AS, Stalmeier PFM, et al. Evaluating the conduct and application of health utility studies: a review of critical appraisal tools and reporting checklists. Eur J Health Econ. 2021;22(5):723-733. doi:10.1007/s10198-021-01286-0

Thanh NX, Jacobs P, Husereau D. Gross profits of Canadian pharmacies: A changing policy regime. Healthc Manage Forum. 2020;33(5):228-232. doi:10.1177/0840470420932185

Patel YP, Husereau D, Leighl NB, Melosky B, Nam J. Health and Budget Impact of Liquid-Biopsy-Based Comprehensive Genomic Profile (CGP) Testing in Tissue-Limited Advanced Non-Small Cell Lung Cancer (aNSCLC) Patients. Curr Oncol. 2021;28(6):5278-5294. doi:10.3390/curroncol28060441

Kristensen FB, Husereau D, Huić M, Drummond M, Berger ML, Bond K, et al. Identifying the Need for Good Practices in Health Technology Assessment: Summary of the ISPOR HTA Council Working Group Report on Good Practices in HTA. Value Health. 2019;22(1):13–20.

Jetty P, Husereau D, Kansal V, Zhang T, Nagpal S. Variability in aneurysm sac regression after endovascular aneurysm repair based on a comprehensive registry of patients in Eastern Ontario. J Vasc Surg. 2019 Nov;70(5):1469–78.

Husereau D, Reed SD. A Beginner’s Guide to Understanding Curative Therapies. Value Health. 2019;22(6):619–20.

Husereau D, Nason E, Ahuja T, Nikaï E, Tsakonas E, Jacobs P. Use of Real-World Data Sources for Canadian Drug Pricing and Reimbursement Decisions: Stakeholder Views and Lessons for Other Countries. Int J Technol Assess Health Care. 2019 Jan;35(3):181–8

Research interests

  • Health Technology Assessment
  • Effective Health Services Based on Sound Scientific Evidence and Equitable Health Policy
  • Drug Reimbursement Policy
  • Evidence Synthesis and Extrapolation